Search results for "P53"

showing 10 items of 303 documents

Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: Contribution of DNA replication, transcription in…

2007

Cyclophosphamide is one of the most often used anticancer drugs. Although DNA interstrand cross-links are considered responsible for its cytotoxicity, the mechanism of initiation and execution of cell death is largely unknown. Using the cyclophosphamide analogue mafosfamide, which does not need metabolic activation, we show that mafosfamide induces apoptosis dose and time dependently in lymphoblastoid cells, with clearly more apoptosis in p53(wt) cells. We identified two upstream processes that initiate apoptosis, DNA replication blockage and transcriptional inhibition. In lymphoblastoid cells, wherein DNA replication can be switched off by tetracycline, proliferation is required for induci…

DNA ReplicationProgrammed cell deathTime FactorsTranscription GeneticDNA damageDrug ResistanceAntineoplastic AgentsApoptosisCell Cycle ProteinsAtaxia Telangiectasia Mutated ProteinsProtein Serine-Threonine KinasesToxicologyCaspase-Dependent ApoptosisCell Linechemistry.chemical_compoundMafosfamideHumansCHEK1PhosphorylationCyclophosphamideCaspaseCell ProliferationPharmacologyDose-Response Relationship DrugbiologyTumor Suppressor ProteinsCell cycleDNA-Binding ProteinsCheckpoint Kinase 2chemistryApoptosisCaspasesCheckpoint Kinase 1Cancer researchbiology.proteinTumor Suppressor Protein p53Protein KinasesSignal TransductionToxicology and Applied Pharmacology
researchProduct

DAZAP2 acts as specifier of the p53 response to DNA damage.

2021

Abstract The DNA damage-responsive tumor suppressors p53 and HIPK2 are well established regulators of cell fate decision-making and regulate the cellular sensitivity to DNA-damaging drugs. Here, we identify Deleted in Azoospermia-associated protein 2 (DAZAP2), a small adaptor protein, as a novel regulator of HIPK2 and specifier of the DNA damage-induced p53 response. Knock-down or genetic deletion of DAZAP2 strongly potentiates cancer cell chemosensitivity both in cells and in vivo using a mouse tumour xenograft model. In unstressed cells, DAZAP2 stimulates HIPK2 polyubiquitination and degradation through interplay with the ubiquitin ligase SIAH1. Upon DNA damage, HIPK2 site-specifically ph…

DNA damageAcademicSubjects/SCI00010Ubiquitin-Protein LigasesRegulatorAntineoplastic AgentsCell fate determinationProtein Serine-Threonine Kinases03 medical and health sciencesMice0302 clinical medicineUbiquitinCell Line TumorGeneticsAnimalsPromoter Regions GeneticGeneMolecular BiologyCells Cultured030304 developmental biologyRegulation of gene expressionCell Nucleus0303 health sciencesbiologyNuclear ProteinsRNA-Binding ProteinsCell biologyUbiquitin ligaseGene Expression Regulation030220 oncology & carcinogenesisCancer cellbiology.proteinTumor Suppressor Protein p53Carrier ProteinsDNA DamageNucleic acids research
researchProduct

The human p53 gene mutated at position 249per se is not sufficient to immortalize human liver cells

1999

A particular point mutation of the tumor suppressor gene p53, namely a G→T transversion at the third base of codon 249, is frequently detected in primary hepatocellular carcinomas from patients living in areas where the levels of dietary exposure to aflatoxin B 1 and the rates of infection with the hepatitis B virus are very high. Very recently, a nontumorigenic liver epithelial cell line (HACL-1) with a finite life-span and expressing a number of hepatocyte-specific markers was established from a human hepatocellular adenoma in our laboratory. To analyze the role of mutated p53 in the immortalization of human liver cells, we transfected HACL-1 cells with an expression vector containing a h…

DNA ComplementaryTumor suppressor geneMutantBiologyTransfectionmedicine.disease_causemedicineHumansCodonCell Line TransformedMutationExpression vectorBase SequenceHepatologyPoint mutationGene Transfer TechniquesDrug Resistance MicrobialTransfectionHepatocellular adenomaGenes p53medicine.diseaseMolecular biologyLiverCell cultureMutationCell DivisionHepatology
researchProduct

Cytotoxic Activity of Organotin(IV) Derivatives with Triazolopyrimidine Containing Exocyclic Oxygen Atoms

2020

In this study cytotoxicity of organotin(IV) compounds with 1,2,4-triazolo[1,5-a]pyrimidines, Me3Sn(5tpO) (1), n-Bu3Sn(5tpO) (2), Me3Sn(mtpO) (3), n-Bu3Sn(mtpO) (4), n-Bu3Sn(HtpO2) (5), Ph3Sn(HtpO2) (6) where 5HtpO = 4,5-dihydro-5-oxo-[1,2,4]triazolo-[1,5-a]pyrimidine, HmtpO = 4,7-dihydro-5-methyl-7-oxo-[1,2,4]triazolo-[1,5-a]pyrimidine, and H2tpO2 = 4,5,6,7-tetrahydro-5,7- dioxo-[1,2,4]triazolo-[1,5-a]-pyrimidine, was assessed on three different human tumor cell lines: HCT-116 (colorectal carcinoma), HepG2 (hepatocarcinoma) and MCF-7 (breast cancer). While 1 and 3 were inactive, compounds 2, 4, 5 and 6 inhibited the growth of the three tumor cell lines with IC50 values in the submicromolar …

DenticityCellPharmaceutical Science01 natural sciencesAnalytical Chemistrychemistry.chemical_compoundDrug DiscoveryOrganotin CompoundstriazolopyrimidineCytotoxicityMembrane Potential MitochondrialCytotoxinsapoptosisBiological activityHep G2 CellsG2 Phase Cell Cycle CheckpointsGene Expression Regulation Neoplasticmedicine.anatomical_structureChemistry (miscellaneous)Mitochondrial MembranesMCF-7 CellsMolecular MedicineCyclin-Dependent Kinase Inhibitor p21crystal structurein vitro anticancer activityPyrimidineCell SurvivalStereochemistryorganotin(iv)010402 general chemistryArticlelcsh:QD241-441Inhibitory Concentration 50Structure-Activity Relationshiplcsh:Organic chemistrymedicineHumansPhysical and Theoretical ChemistryMetallodrug010405 organic chemistryLigandOrganic ChemistryTriazolesHCT116 CellsapoptosiG1 Phase Cell Cycle Checkpoints0104 chemical sciencesPyrimidineschemistrymetallodrugsCell cultureApoptosisDrug DesignTumor Suppressor Protein p53Reactive Oxygen SpeciesMolecules
researchProduct

Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.

2009

Abstract Coadministration of the iron chelator dexrazoxane reduces by 80% the incidence of heart failure in cancer patients treated with anthracyclines. The clinical application of dexrazoxane is limited, however, because its ability to inhibit topoisomerase IIα (TOP2A) is feared to adversely affect anthracycline chemotherapy, which involves TOP2A-mediated generation of DNA double-strand breaks (DSB). Here, we investigated the apoptotic effects of dexrazoxane and the anthracycline doxorubicin, alone and in combination, in a tumor cell line with conditionally regulated expression of TOP2A. Each drug caused apoptosis that was only partly dependent on TOP2A. Unexpectedly, dexrazoxane was found…

DrugCancer ResearchAnthracyclinemedicine.medical_treatmentmedia_common.quotation_subjectAntineoplastic AgentsApoptosisPharmacologyHistonesAntigens NeoplasmCell Line TumormedicineHumansDoxorubicinAdverse effectPoly-ADP-Ribose Binding Proteinsmedia_commonCaspase 7ChemotherapyChemistryCaspase 3Gene Expression ProfilingCancermedicine.diseaseGlutathioneDNA-Binding ProteinsGene Expression Regulation NeoplasticDNA Topoisomerases Type IIOncologyApoptosisDoxorubicinCancer researchDexrazoxaneTumor Suppressor Protein p53Razoxanemedicine.drugMolecular cancer therapeutics
researchProduct

Rol del complejo RUNX1-CBF-β/HIPK2/p300/p53 en la evolución leucémica de las neoplasias mieloproliferativas crónicas

2019

Las neoplasias mieloproliferativas crónicas (NMPs) son procesos cancerígenos en los que se produce una expansión clonal de una o varias poblaciones de progenitores hematopoyéticos de estirpe mieloide. En las fases iniciales de la enfermedad, éstos presentan una adecuada diferenciación celular, lo que conlleva una descompensación final de los diferentes tipos celulares en médula ósea y sangre periférica y la consiguiente aparición de una serie de síntomas asociados que pueden llegar a producir importantes citopenias o complicaciones vasculares. A pesar de que las NMPs pueden mantenerse relativamente controladas en su fase crónica mediante un tratamiento adecuado, éstas patologías tienen una …

EP300RUNX1leucemogénesisMFapoptosisPVHIPK2leucemia mieloide:CIENCIAS DE LA VIDA [UNESCO]proliferaciónNeoplasias mieloproliferativasUNESCO::CIENCIAS DE LA VIDAhematopoyesisciclo celularTP53NMPsLMCCBF-βTE
researchProduct

The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.

1998

Many anticancer drugs are able to induce apoptosis in tumor cells but the mechanisms underlying this phenomenon are poorly understood. Some authors reported that the p53 tumor suppressor gene may be responsible for drug-induced apoptosis; however, chemotherapy-induced apoptosis can also be observed in p53 negative cells. Recently, doxorubicin (DXR) was reported to induce CD95L expression to mediate apoptosis through the CD95/CD95L system. Thus, an impairment of such a system may be involved in drug resistance. We evaluated the in vitro antitumor activity of several cytotoxic drugs on two human p53-negative T-cell lymphoma cell lines, the HUT78-B1 CD95L-resistant cell line and the HUT78 pare…

Fas Ligand ProteinCaspase 3Antineoplastic AgentsApoptosismedicineTumor Cells CulturedCytotoxic T cellHumansfas ReceptorCytotoxicityMolecular BiologyEtoposideEtoposideMembrane GlycoproteinsChemistryCaspase 3Cell BiologyFas receptorCaspase InhibitorsProto-Oncogene Proteins c-bcl-2Cell cultureApoptosisDoxorubicinCaspasesCancer researchTumor Suppressor Protein p53Camptothecinmedicine.drugCell death and differentiation
researchProduct

Defective apoptosis and tumorigenesis: role of p53 mutation and Fas/FasL system dysregulation

2010

The transcription factor p53 and the cytokine receptor FasL are two of the most famous regulators of cell life, and their alterations can cause a large number of pathologies, including cancer. In this review, we focused on how they can determine defective apoptosis, one of the causes of tumorigenesis and tumor progression. The importance of this knowledge lies in the new perspectives that gene therapy can offer to cure cancer.

Fas Ligand ProteinHistologyFree RadicalsCellBiophysicsApoptosisBiologymedicine.disease_causeFas ligandNeoplasmsmedicineAnimalsHumansfas ReceptorTranscription factorlcsh:QH301-705.5Membrane GlycoproteinsfungiCancerfood and beveragesGenetic TherapyCell BiologyGenes p53medicine.diseaseGenes bcl-2medicine.anatomical_structurelcsh:Biology (General)ApoptosisTumor progressionImmunologyCarcinogenesisCytokine receptorEuropean Journal of Histochemistry
researchProduct

p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation.

2003

The mechanism of p53-dependent apoptosis is still only partly defined. Using early-passage embryonic fibroblasts (MEF) from wild-type (wt), p53(-/-) and bax(-/-) mice, we observe a p53-dependent translocation of Bax to the mitochondria and a release of mitochondrial Cytochrome c during stress-induced apoptosis. These events proceed independent of zVAD-inhibitable caspase activation, are not prevented by dominant negative FADD (DN-FADD), but are negatively regulated by Mdm-2. Bcl-x(L) expression prevents the release of mitochondrial Cytochrome c and apoptosis, but not Bax translocation. At a single-cell level, enforced expression of p53 is sufficient to induce Bax translocation and Cytochrom…

Fas-Associated Death Domain ProteinDown-RegulationChromosomal translocationApoptosisCytochrome c GroupMitochondrionMiceBcl-2-associated X proteinFetusDownregulation and upregulationProto-Oncogene ProteinsAnimalsFADDEnzyme InhibitorsMolecular BiologyCells CulturedAdaptor Proteins Signal Transducingbcl-2-Associated X ProteinMice KnockoutbiologyOncogeneChemistryCytochrome cCell BiologyFibroblastsMolecular biologyCell biologyMitochondriaProtein TransportGene Expression RegulationProto-Oncogene Proteins c-bcl-2ApoptosisCaspasesbiology.proteinTumor Suppressor Protein p53Carrier ProteinsCell death and differentiation
researchProduct

Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: Oxyradical overload diseases

2000

Hemochromatosis and Wilson disease (WD), characterized by the excess hepatic deposition of iron and copper, respectively, produce oxidative stress and increase the risk of liver cancer. Because the frequency of p53 mutated alleles in nontumorous human tissue may be a biomarker of oxyradical damage and identify individuals at increased cancer risk, we have determined the frequency of p53 mutated alleles in nontumorous liver tissue from WD and hemochromatosis patients. When compared with the liver samples from normal controls, higher frequencies of G:C to T:A transversions at codon 249 ( P < 0.001) and C:G to A:T transversions and C:G to T:A transitions at codon 250 ( P < 0.001 and P &…

Free RadicalsIronGenes MHC Class INitric Oxide Synthase Type IIBiologymedicine.disease_causeNitric oxideCell LineLipid peroxidationchemistry.chemical_compoundHepatolenticular DegenerationHLA AntigensmedicineAnimalsHumansAlleleHemochromatosis ProteinHemochromatosisMutationAldehydesMultidisciplinaryHistocompatibility Antigens Class IMembrane ProteinsBiological Sciencesmedicine.diseaseMolecular biologyNitric oxide synthasechemistryLiverMutagenesisImmunologyMutationbiology.proteinHemochromatosisRabbitsNitric Oxide SynthaseTumor Suppressor Protein p53Liver cancerOxidative stressCopper
researchProduct